News

TBVI Releases 2009 Annual Report

5 Jul 2010
by Working Group
TB News
vaccines

From the TBVI website: http://www.tbvi.eu/news-agenda/tbvi-news/news-message/tbvi-annual-report-2009-released.html

TBVI 2009 Annual Report
TBVI 2009 Annual Report

TuBerculosis Vaccine Initiative (TBVI), a foundation that aims to develop new vaccines for tuberculosis, today released its annual report 2009.

In 2009 TBVI made significant progress in its overall objective to develop new vaccines for tuberculosis. Preceded by many years of research and development, last year four vaccine candidates moved from discovery phase to early clinical development. Furthermore, TBVI expanded its network with several new research partners and completed the formation of its Board of Trustees.

Last year wealso successfully acquired new funding that has strengthened our organisation and secured continued support for R&D activities carried out by our partners.

The annual report gives a further overview of our advancements, our work and our partners.

Jelle Thole,
Director TBVI

More News
22 Jul 2024

With NIH Funding, A New Consortium Aims to Improve TB Treatment

The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024

WHO Released Its Updated Bacterial Priority Pathogens List

On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024

Most Robust TB Drug Pipeline in History

For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...